Supreme Court directs Centre to form panel on pharma ethics

The Supreme Court of India has issued directions to the Centre to constitute a committee tasked with ensuring pharmaceutical firms adhere to ethical standards and refrain from engaging in malpractices. The judicial intervention underscores growing concerns about conduct within the pharmaceutical sector and the need for enhanced regulatory mechanisms.

The court's directive reflects ongoing scrutiny of the pharmaceutical industry's business practices, including pricing strategies, marketing methods, and product quality standards. By establishing a dedicated committee, the government is expected to create a structured framework for monitoring compliance and addressing violations more effectively.

The proposed committee is anticipated to work in coordination with existing regulatory bodies such as the Drugs Controller General of India and the Central Drugs Standard Control Organisation. Its mandate would likely encompass investigation of complaints, enforcement of ethical guidelines, and recommendations for policy improvements.

The Supreme Court's intervention comes as regulators worldwide intensify focus on pharmaceutical sector accountability. India, as a major pharmaceutical hub supplying medicines globally, faces particular scrutiny regarding industry practices and patient welfare protections. The formation of such a committee is expected to strengthen the nation's regulatory architecture and reinforce confidence in the sector's governance standards.